Get Access to Vemurafenib in India

Vemurafenib is an oral medication that falls under the category of kinase inhibitors. This class of drugs are known for preventing the multiplication of cancer cells by blocking the abnormal protein synthesis. Available as Zelboraf 240mg tablets, Vemurafenib is a drug recommended in the management of late-stage melanoma. This medication was approved by FDA in 2011. EMA approval was granted in 2012. Later in 2017, its indication was expended to Erdheim–Chester disease (ECD) after its FDA approval. ECD is a rare disorder.

Vemurafenib in India for patients is available through import channels. In melanoma patients with V600E BRAF mutation, Zelboraf is prescribed and therefore confirming V600E BRAF is important. This drug is also being used in Thyroid and Non-small cell lung cancers with V600E BRAF mutation; these are of course orphan indications. This drug was developed by Genentech and is now promoted by Roche worldwide. It is mostly accessible from the western European countries. USA, Canada, UK and Germany are the countries are preferred by patients to import.

Oral non cold chain medications are relatively easy to access and manage the import. But, there are specific limitations when it comes to freely accessible medications. The regulatory requirements remain the same. Vemurafenib is also used in combination of other drugs like cobimetinib in melanoma treatment. This combination treatment is known to result in anti-proliferative effects that slow spread of the cancer.